Iron deficiency in patients with renal failure

Area of Science:

• Nephrology
• Hematology
• Internal Medicine

Background:

• Anemia is a common complication of renal failure, primarily due to insufficient endogenous erythropoietin.
• Recombinant human erythropoietin (rHuEPO) therapy has revolutionized anemia treatment in dialysis patients.
• Effective anemia management with rHuEPO necessitates addressing iron status.

Purpose of the Study:

• To highlight the critical role of iron management in patients with renal failure receiving rHuEPO.
• To explain the mechanisms leading to iron deficiency in dialysis patients undergoing rHuEPO therapy.
• To emphasize the importance of understanding iron metabolism for optimizing anemia treatment.

Main Methods:

• Review of existing literature on anemia of renal failure and iron metabolism.
• Analysis of iron requirements in hemodialysis and peritoneal dialysis patients treated with rHuEPO.
• Discussion of factors contributing to iron deficiency in this patient population.

Main Results:

• Most dialysis patients on rHuEPO develop iron deficiency, either absolute or functional.
• Increased iron demand from accelerated erythropoiesis and blood losses contribute to deficiency.
• Peritoneal dialysis patients may also experience iron deficiency due to poor intake and increased demand.

Conclusions:

• Proper iron replacement is essential for achieving target hematocrit levels in patients treated with rHuEPO.
• Renal health professionals must understand iron metabolism to effectively manage anemia in dialysis patients.
• A balanced approach combining rHuEPO and supplemental iron is crucial for optimal therapeutic outcomes.